These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31188728)

  • 21. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
    Bauer SR; Walter LC; Ensrud KE; Suskind AM; Newman JC; Ricke WA; Liu TT; McVary KT; Covinsky K
    JAMA Netw Open; 2021 Nov; 4(11):e2134427. PubMed ID: 34817584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How effective is finasteride?].
    Krome S
    Dtsch Med Wochenschr; 2011 Feb; 136(8):354. PubMed ID: 21348003
    [No Abstract]   [Full Text] [Related]  

  • 24. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
    Bhardwa J; Goldstraw M; Tzortzis S; Kirby R
    Expert Opin Pharmacother; 2007 Jun; 8(9):1337-44. PubMed ID: 17563267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
    Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
    BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5alpha-reductase inhibitors: what role should they play?
    Kaplan SA
    Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.
    Fornari A; Rhoden EL; Zettler CG; Ribeiro EP; Rhoden CR
    Int Urol Nephrol; 2011 Mar; 43(1):39-45. PubMed ID: 20532625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia.
    Roehrborn CG; Rukstalis DB
    Eur Urol Focus; 2022 Jan; 8(1):217-227. PubMed ID: 33436276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
    Alcántara-Montero A; Brenes-Bermúdez FJ
    Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
    [No Abstract]   [Full Text] [Related]  

  • 34. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia.
    Baldwin KC; Ginsberg PC; Roehrborn CG; Harkaway RC
    Urology; 2001 Aug; 58(2):203-9. PubMed ID: 11489700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Finasteride in the treatment of benign prostatic hyperplasia].
    Ząbkowski T
    Urologe A; 2012 Jul; 51(7):982-6. PubMed ID: 22772497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death.
    Welk B; McClure JA
    J Urol; 2023 Oct; 210(4):670-677. PubMed ID: 37681541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.